Pyxis Oncology, Inc. (PYXS)
PYXS moved a median of +0.19% 30 minutes after news, and 0.00% by the close. How PYXS actually reacts to news — the realized, point-in-time move the market made, measured across 209 labeled events over the last three years with zero look-ahead.
PYXS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.48% | 60% | 208 |
| 30-min | +0.19% | 55% | 209 |
| 60-min | +0.53% | 55% | 209 |
| to close | 0.00% | 49% | 209 |
| Middle 50% of PYXS reactions | -1.82% to +3.77% |
|---|---|
| Median reaction (30-min) | +0.19% |
| Measured reactions | 209 |
Half of all Pyxis Oncology, Inc. news events land between -1.82% and +3.77% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How PYXS reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 10 | +0.48% | 60% | +0.89% |
| Analyst downgrades | 10 | -0.03% | 50% | -3.23% |
| Coverage initiations | 26 | +1.76% | 77% | +7.31% |
| Rating reiterations | 46 | -0.46% | 44% | -2.33% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how PYXS ranks against every other measured name →
That’s how PYXS usually reacts — get an email when it moves on news →Email me when PYXS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PYXS's baseline. Nothing else.
Recent PYXS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form PRE 14A Pyxis Oncology, Inc. For: Oct 09 | SEC filing · Form PRE | SEC EDGAR | +0.49% | -0.98% | |
| Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering | Press release | GlobeNewswire | -2.71% | -3.17% | |
| Form 8-K Pyxis Oncology, Inc. For: Sep 29 | SEC filing · Form 8-K | SEC EDGAR | -2.71% | -3.17% | |
| Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering | Press release | GlobeNewswire | -3.13% | -2.92% | |
| Pyxis Oncology Announces Proposed Public Offering | Press release | GlobeNewswire | -3.13% | -2.92% | |
| Form 8-K Pyxis Oncology, Inc. For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | +3.16% | -2.87% | |
| Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) | Press release | GlobeNewswire | +3.16% | -2.87% | |
| Form 8-K Pyxis Oncology, Inc. For: Sep 03 | SEC filing · Form 8-K | SEC EDGAR | +0.50% | -2.75% | |
| Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board | Press release | GlobeNewswire | +0.50% | -2.75% | |
| Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC) | Press release | GlobeNewswire | +3.16% | -2.87% | |
| Pyxis Oncology to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.93% | +6.17% | |
| Form EFFECT Pyxis Oncology, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -1.02% | -2.71% | |
| Form S-3 Pyxis Oncology, Inc. | SEC filing · Form S-3 | SEC EDGAR | +0.48% | -0.96% | |
| Form 10-Q Pyxis Oncology, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.03% | +2.03% | |
| Form 8-K Pyxis Oncology, Inc. For: Aug 13 | SEC filing · Form 8-K | SEC EDGAR | +2.03% | +2.03% | |
| Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones | Press release | GlobeNewswire | +2.03% | +2.03% | |
| Form 8-K Pyxis Oncology, Inc. For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | -3.21% | -7.17% | |
| Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones | Press release | GlobeNewswire | +8.84% | +20.88% | |
| Form 8-K Pyxis Oncology, Inc. For: Jun 15 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.57% | |
| Form 10-Q Pyxis Oncology, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -13.21% | -16.60% | |
| Form 8-K Pyxis Oncology, Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -13.21% | -16.60% | |
| Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones | Press release | GlobeNewswire | -13.21% | -16.60% | |
| Pyxis Oncology to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.96% | +1.16% | |
| Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer | Press release | GlobeNewswire | +3.74% | +20.70% | |
| Form 8-K/A Pyxis Oncology, Inc. For: Feb 06 | SEC filing · Form 8-K | SEC EDGAR | +2.14% | +3.03% | |
| Form ARS Pyxis Oncology, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +2.14% | +3.03% | |
| Form DEF 14A Pyxis Oncology, Inc. For: Apr 30 | SEC filing · Form DEF | SEC EDGAR | +2.14% | +3.03% | |
| Form DEFA14A Pyxis Oncology, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +2.14% | +3.03% | |
| Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026 | Press release | GlobeNewswire | +3.69% | +3.03% | |
| Form 10-K Pyxis Oncology, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.67% | -5.33% | |
| Form 8-K Pyxis Oncology, Inc. For: Mar 23 | SEC filing · Form 8-K | SEC EDGAR | +0.67% | -5.33% | |
| Form S-8 Pyxis Oncology, Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.00% | -5.56% | |
| Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | +0.67% | -5.33% | |
| Form 8-K Pyxis Oncology, Inc. For: Feb 06 | SEC filing · Form 8-K | SEC EDGAR | -0.05% | -9.87% | |
| Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity | Press release | GlobeNewswire | +5.30% | -1.32% | |
| Form 8-K Pyxis Oncology, Inc. For: Dec 18 | SEC filing · Form 8-K | SEC EDGAR | -2.65% | +1.76% | |
| Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Press release | GlobeNewswire | -2.65% | +1.76% | |
| Form EFFECT Pyxis Oncology, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.23% | +0.23% | |
| Form S-3 Pyxis Oncology, Inc. | SEC filing · Form S-3 | SEC EDGAR | +0.65% | -1.31% | |
| Form 10-Q Pyxis Oncology, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +4.60% | +9.48% | |
| Form 8-K Pyxis Oncology, Inc. For: Nov 03 | SEC filing · Form 8-K | SEC EDGAR | +4.60% | +9.48% | |
| Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results | Press release | GlobeNewswire | +4.60% | +9.48% | |
| Pyxis Oncology to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -5.73% | +1.56% | |
| Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings | Press release | GlobeNewswire | -0.88% | -5.56% | |
| Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets | Press release | GlobeNewswire | +1.66% | +31.61% | |
| Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +2.27% | -0.46% | |
| Pyxis Oncology to Participate in September Investor and Industry Conferences | Press release | GlobeNewswire | +7.02% | +15.79% | |
| Form 10-Q Pyxis Oncology, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +6.96% | |
| Form 8-K Pyxis Oncology, Inc. For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +6.96% | |
| Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | GlobeNewswire | +0.00% | +6.96% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PYXS section they belong to.
Where else PYXS is measured.
PYXS earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Pyxis Oncology, Inc.'s median reaction calculated?
Every labeled PYXS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 209 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 55% of PYXS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PYXS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.